Maria Guillily
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maria Guillily has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Wolozin
Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, USA
1 shared publication - Carmela R. Abraham
Departments of Biochemistry and Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, USA
1 shared publication - Celina V. Zerbinatti
Department of Neurosymptomatic Disorders, Merck Research Laboratories, West Point, PA 19486, USA
1 shared publication - Ci-Di Chen
Klogene Therapeutics, Inc Boston MA USA
1 shared publication - Guy R. Seabrook
Merck Research Laboratories
1 shared publication - Joanna M Cordy
Department of Pharmacology, Boston University School of Medicine, Boston, MA, 02118, USA
1 shared publication
Latest Publications
- Open Access
- 18 March 2008
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 3 (1) , 5
Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein
Background: Evidence from biochemical, epidemiological and genetic findings indicates that cholesterol levels are linked to amyloid-β (Aβ) production and Alzheimer's disease (AD). Oxysterols, which are cholesterol-derived ligands of the liver X receptors (LXRs) and oxysterol binding proteins, strongly regulate the processing of amyloid precursor protein (APP). Although LXRs have been studied extensively, little is known about the biology of oxysterol binding proteins. Oxysterol-binding protein 1 (OSBP1) is a member of a family of sterol-binding proteins with roles in lipid metabolism, regulation of secretory vesicle generation and signal transduction, and it is thought that these proteins may act as sterol sensors to control a variety of sterol-dependent cellular processes. Results: We investigated whether OSBP1 was involved in regulating APP processing and found that overexpression of OSBP1 downregulated the amyloidogenic processing of APP, while OSBP1 knockdown had the opposite effect. In addition, we found that OSBP1 altered the trafficking of APP-Notch2 dimers by causing their accumulation in the Golgi, an effect that could be reversed by treating cells with OSBP1 ligand, 25-hydroxycholesterol. Conclusion: These results suggest that OSBP1 could play a role in linking cholesterol metabolism with intracellular APP trafficking and Aβ production, and more importantly indicate that OSBP1 could provide an alternative target for Aβ-directed therapeutic.
- 18 March 2008
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 3 (1) , 5
Open AccessOxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein
Background: Evidence from biochemical, epidemiological and genetic findings indicates that cholesterol levels are linked to amyloid-β (Aβ) production and Alzheimer's disease (AD). Oxysterols, which are cholesterol-derived ligands of the liver X receptors (LXRs) and oxysterol binding proteins, strongly regulate the processing of amyloid precursor protein (APP). Although LXRs have been studied extensively, little is known about the biology of oxysterol binding proteins. Oxysterol-binding protein 1 (OSBP1) is a member of a family of sterol-binding proteins with roles in lipid metabolism, regulation of secretory vesicle generation and signal transduction, and it is thought that these proteins may act as sterol sensors to control a variety of sterol-dependent cellular processes. Results: We investigated whether OSBP1 was involved in regulating APP processing and found that overexpression of OSBP1 downregulated the amyloidogenic processing of APP, while OSBP1 knockdown had the opposite effect. In addition, we found that OSBP1 altered the trafficking of APP-Notch2 dimers by causing their accumulation in the Golgi, an effect that could be reversed by treating cells with OSBP1 ligand, 25-hydroxycholesterol. Conclusion: These results suggest that OSBP1 could play a role in linking cholesterol metabolism with intracellular APP trafficking and Aβ production, and more importantly indicate that OSBP1 could provide an alternative target for Aβ-directed therapeutic.